The Kidney TRUST
kidneytrust.org/new/the-kidney-trust-adds-two-corporate-leaders-to-board-of-directors/

The TRUST Adds Two Corporate Leaders to Board of Directors

January 13, 2022 – Burlingame, California – The Kidney TRUST, a national non-profit organization dedicated to reducing the human and economic cost of kidney disease, has named Roy Malkin, president & CEO of Minntech Corporation, and Derrick Donald, national accounts director for the renal division of Genzyme Corporation, as members of the TRUST’s board of directors.

I’m very pleased to have two such dedicated and passionate individuals join our board,” said TRUST President & CEO Annette Eros.  “Roy and Derrick have extensive experience working in the renal industry and share with me a personal commitment to raising awareness about chronic kidney disease and reducing the personal and societal toll of this serious condition, which now affects over 31 million Americans.”

 Roy K. Malkin is president and chief executive officer of Minntech Corporation, a subsidiary of Cantel Medical Corporation, a position he has held since September 2001.  Minntech is a publicly-held company based in Minneapolis that manufactures and markets medical devices, sterilants, and blood and water filtration products, many of which are used in dialysis.  

Derrick S. Donald is national accounts director in the renal division at Genzyme, a position he has held since 2008.  Prior to that, Donald was national account manager and clinical science specialist, both at Genzyme.  Genzyme is one of the world’s leading biotechnology companies – its products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant, and immune disease.

About The Kidney TRUST

The Kidney TRUST’s free rapid-screening program, which has reached nearly 15,000 people since the program was launched in October 2007, identifies individuals who have signs of kidney impairment. Along with learning their screening results onsite, participants benefit from a personal education session to explain their results and any individual risk factors, receive materials that offer additional education about CKD and its prevention, and are encouraged to seek medical follow-up as appropriate. The TRUST also focuses on the unmet needs of people who have CKD through its Financial Assistance program (FAP) for people on dialysis. The FAP has awarded more than 1,000 grants totaling nearly $2.2 million in the last two years.  Visit www.kidneytrust.org for more information.